BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 7636216)

  • 1. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
    J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS; Anasetti C; Tso JY
    J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
    Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
    J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11).
    Henrickson M; Reid J; Bellet JS; Sawchuk SS; Hirsch R
    Transplantation; 1995 Oct; 60(8):828-35. PubMed ID: 7482743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC; Tibbe GJ; Kroos MJ; van de Winkel JG; Benner R; Savelkoul HF
    Eur J Immunol; 1995 Jun; 25(6):1492-6. PubMed ID: 7614975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab')2) anti-CD3 monoclonal antibody.
    Sawchuk SS; Gates R; Hirsch R
    Transplantation; 1995 Dec; 60(11):1331-7. PubMed ID: 8525530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of five humanized OKT3 effector function variant antibodies.
    Xu D; Alegre ML; Varga SS; Rothermel AL; Collins AM; Pulito VL; Hanna LS; Dolan KP; Parren PW; Bluestone JA; Jolliffe LK; Zivin RA
    Cell Immunol; 2000 Feb; 200(1):16-26. PubMed ID: 10716879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
    J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
    Scallon B; McCarthy S; Radewonuk J; Cai A; Naso M; Raju TS; Capocasale R
    Int Immunopharmacol; 2007 Jun; 7(6):761-72. PubMed ID: 17466910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.
    Haagen IA; Geerars AJ; Clark MR; van de Winkel JG
    J Immunol; 1995 Feb; 154(4):1852-60. PubMed ID: 7836769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.
    Eto M; Yoshikai Y; Nishimura Y; Hiromatsu K; Maeda T; Nomoto K; Kong YY; Kubo RT; Kumazawa J; Nomoto K
    Immunology; 1994 Feb; 81(2):198-204. PubMed ID: 8157269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
    Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody.
    Routledge EG; Falconer ME; Pope H; Lloyd IS; Waldmann H
    Transplantation; 1995 Oct; 60(8):847-53. PubMed ID: 7482746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody.
    Graziano RF; Tempest PR; White P; Keler T; Deo Y; Ghebremariam H; Coleman K; Pfefferkorn LC; Fanger MW; Guyre PM
    J Immunol; 1995 Nov; 155(10):4996-5002. PubMed ID: 7594506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo immunosuppression induced by a weakly mitogenic antibody to mouse CD3: evidence that induction of long-lasting in vivo unresponsiveness requires TcR signaling.
    Flamand V; Donckier V; Abramowicz D; Goldman M; Vandenabeele P; Urbain J; Moser M; Leo O
    Cell Immunol; 1994 Aug; 157(1):239-48. PubMed ID: 8039247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone.
    Alegre ML; Vandenabeele P; Depierreux M; Florquin S; Deschodt-Lanckman M; Flamand V; Moser M; Leo O; Urbain J; Fiers W
    J Immunol; 1991 Feb; 146(4):1184-91. PubMed ID: 1825107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.